DEFINE - a Randomized, Open-Label Trial of the Inhaled Galectin-3 Inhibitor GB0139 in Hospitalized Patients with Moderate-to-Severe COVID-19

Gaughan, E.; Sethi, T.; Quinn, T.; Hirnani, N.; Mills, A.; Bruce, A. M.; Mackinnon, A.; Aslanis, V.; Li, F.; O'Connor, R.; Dear, J.; Akram, A. R.; Koch, O.; Wang-Jairaj, J.; Slack, R. J.; Gravelle, L.; Lindmark, B.; Dhaliwal, K.

Gaughan, E.; Sethi, T.; Quinn, T.; Hirnani, N.; Mills, A.; Bruce, A. M.; Mackinnon, A.; Aslanis, V.; Li, F.; O'Connor, R.; Dear, J.; Akram, A. R.; Koch, O.; Wang-Jairaj, J.; Slack, R. J.; Gravelle, L.; Lindmark, B.; Dhaliwal, K..

American Journal of Respiratory and Critical Care Medicine ; 205:2, 2022.

Article in English | English Web of Science | ID: covidwho-1880252

Keywords

General & Internal Medicine; Respiratory System

Search on Google

XML

Collection: Databases of international organizations Database: English Web of Science Type of study: Experimental Studies / Randomized controlled trials Language: English Journal: American Journal of Respiratory and Critical Care Medicine Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML